Publication Date:
2014-07-22
Description:
FOXP3(+) regulatory T cells (Treg cells) are abundant in the intestine, where they prevent dysregulated inflammatory responses to self and environmental stimuli. It is now appreciated that Treg cells acquire tissue-specific adaptations that facilitate their survival and function; however, key host factors controlling the Treg response in the intestine are poorly understood. The interleukin (IL)-1 family member IL-33 is constitutively expressed in epithelial cells at barrier sites, where it functions as an endogenous danger signal, or alarmin, in response to tissue damage. Recent studies in humans have described high levels of IL-33 in inflamed lesions of inflammatory bowel disease patients, suggesting a role for this cytokine in disease pathogenesis. In the intestine, both protective and pathological roles for IL-33 have been described in murine models of acute colitis, but its contribution to chronic inflammation remains ill defined. Here we show in mice that the IL-33 receptor ST2 is preferentially expressed on colonic Treg cells, where it promotes Treg function and adaptation to the inflammatory environment. IL-33 signalling in T cells stimulates Treg responses in several ways. First, it enhances transforming growth factor (TGF)-beta1-mediated differentiation of Treg cells and, second, it provides a necessary signal for Treg-cell accumulation and maintenance in inflamed tissues. Strikingly, IL-23, a key pro-inflammatory cytokine in the pathogenesis of inflammatory bowel disease, restrained Treg responses through inhibition of IL-33 responsiveness. These results demonstrate a hitherto unrecognized link between an endogenous mediator of tissue damage and a major anti-inflammatory pathway, and suggest that the balance between IL-33 and IL-23 may be a key controller of intestinal immune responses.〈br /〉〈br /〉〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339042/" target="_blank"〉〈img src="https://static.pubmed.gov/portal/portal3rc.fcgi/4089621/img/3977009" border="0"〉〈/a〉 〈a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4339042/" target="_blank"〉This paper as free author manuscript - peer-reviewed and accepted for publication〈/a〉〈br /〉〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Schiering, Chris -- Krausgruber, Thomas -- Chomka, Agnieszka -- Frohlich, Anja -- Adelmann, Krista -- Wohlfert, Elizabeth A -- Pott, Johanna -- Griseri, Thibault -- Bollrath, Julia -- Hegazy, Ahmed N -- Harrison, Oliver J -- Owens, Benjamin M J -- Lohning, Max -- Belkaid, Yasmine -- Fallon, Padraic G -- Powrie, Fiona -- 086335/Wellcome Trust/United Kingdom -- 095688/Wellcome Trust/United Kingdom -- 097109/Wellcome Trust/United Kingdom -- 099814/Wellcome Trust/United Kingdom -- Wellcome Trust/United Kingdom -- England -- Nature. 2014 Sep 25;513(7519):564-8. doi: 10.1038/nature13577. Epub 2014 Jul 16.〈br /〉〈span class="detail_caption"〉Author address: 〈/span〉1] Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK [2] Division of Molecular Immunology, MRC National Institute for Medical Research, Mill Hill, London NW7 1AA, UK (C.S.); Department of Microbiology and Immunology, School of Medicine and Biomedical Sciences, University at Buffalo (SUNY), Buffalo, New York 14214-3000, USA (E.A.W.). [3]. ; 1] Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK [2]. ; Translational Gastroenterology Unit, Nuffield Department of Clinical Medicine, Experimental Medicine Division, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DU, UK. ; Experimental Immunology, Department of Rheumatology and Clinical Immunology, Charite - University Medicine Berlin, and German Rheumatism Research Center (DRFZ), D-10117 Berlin, Germany. ; 1] Program in Barrier Immunity and Repair, Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892, USA [2] Division of Molecular Immunology, MRC National Institute for Medical Research, Mill Hill, London NW7 1AA, UK (C.S.); Department of Microbiology and Immunology, School of Medicine and Biomedical Sciences, University at Buffalo (SUNY), Buffalo, New York 14214-3000, USA (E.A.W.). ; Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford OX1 3RE, UK. ; Program in Barrier Immunity and Repair, Mucosal Immunology Section, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, Maryland 20892, USA. ; Trinity Biomedical Sciences Institute, Trinity College Dublin, Pearse Street, Dublin 2, Ireland.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/25043027" target="_blank"〉PubMed〈/a〉
Keywords:
Animals
;
Colitis/immunology/pathology
;
Colon/cytology/immunology/pathology
;
Disease Models, Animal
;
Female
;
Immunity, Mucosal
;
Inflammation/immunology/metabolism/pathology
;
Interleukin-23/immunology
;
Interleukin-33
;
Interleukins/antagonists & inhibitors/*immunology/metabolism
;
Intestines/*cytology/*immunology/pathology
;
Male
;
Mice
;
Mice, Inbred C57BL
;
Receptors, Interleukin/metabolism
;
Signal Transduction/immunology
;
T-Lymphocytes, Regulatory/cytology/*immunology
;
Thymus Gland/cytology
;
Transforming Growth Factor beta/metabolism
Print ISSN:
0028-0836
Electronic ISSN:
1476-4687
Topics:
Biology
,
Chemistry and Pharmacology
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
